Here, we present the results for a melanoma expansion-cohort of a phase 1B multicenter, open-label study, in which the efficacy and safety of treatment with a ziv-aflibercept plus pembrolizumab in patients with advanced PD-1-resistant melanoma, renal cancer, and sarcoma were examined. The gene discussed is PDCD1; the disease is renal carcinoma.